What are the literatures about Intel's recombinant collagen iii?

The literature of Intel's recombinant type ⅲ collagen includes the expression of long-acting recombinant type ⅲ collagen by Saccharomyces cerevisiae and its application in cosmetics. Relevant information shows that the patent was granted by the patentee Wuhu Interfield Biological Products Industry Research Institute Co., Ltd. on April 19, 2022, and the amino acid sequence of long-acting recombinant collagen III includes basic repeating units and terminal amino acid sequences. The long-acting recombinant type III collagen of the invention has good biocompatibility and cell adhesion, can promote the formation of new cells, has a hemostatic function, and has a strong function of promoting the growth of epithelial cells. Compared with collagen extracted from animal tissues and xenografts, the long-acting recombinant type III collagen of the invention has the advantages of solubility, no virus hidden danger and low rejection reaction.